TBPH vs UCFI
TBPH: A commercial-stage biopharmaceutical company primarily focused on its COPD therapy, YUPELRI, currently navigating a strategic review and pending merger. UCFI: A biotechnology-driven health food company specializing in grain-based products that integrate traditional Chinese medicine, currently navigating significant regulatory and listing challenges.
Side-by-side fundamentals
| Metric | TBPH | UCFI | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $17.03 | $5.51 | |
| Market cap | $884M | $288M | |
| P/E as of 2026-10-08 | 7.73 | 66.55 | TBPH lower |
| Net margin FY2025, SEC XBRL | +98.5% | n/a | |
| Operating margin FY2025, SEC XBRL | -3.4% | n/a | |
| ROE FY2025, SEC XBRL | +35.7% | n/a | |
| ROA | +21.8% | +1.9% | TBPH higher |
| Debt / equity as of 2026-09-02 | 0.11 | 0.18 | TBPH lower |
| Revenue growth (YoY) as of 2026-09-02 | +68.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.57 | 0.06 | |
| 1-year return as of 2026-10-08 close | +17.9% | +0.0% | TBPH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.